Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.54 |
| ▸ | ALB | P02768 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5503660 | 0.88 | TTR (0.43) | TTRALBKDM4EXDHALDH1A1 | |
| SCHEMBL22197816 | 0.84 | TTR (0.58) | TTRALBKDM4EXDHALDH1A1 | |
| SCHEMBL1182463 | 0.84 | ALDH1A1 (0.50) | TTRALBKDM4EXDHALDH1A1 | |
| SCHEMBL30464787 | 0.82 | ALDH1A1 (0.48) | TTRALBKDM4EXDHALDH1A1 | |
| SCHEMBL27254466 | 0.78 | TTR (0.58) | TTRALBALDH1A1CYP2A6EGLN2 | |
| SCHEMBL2339085 | 0.78 | ALDH1A1 (0.39) | TTRALBKDM4EXDHALDH1A1 | |
| SCHEMBL24193570 | 0.77 | TTR (0.83) | TTRALBKDM4EALDH1A1CYP2A6 | |
| SCHEMBL11685893 | 0.77 | ALDH1A1 (0.37) | TTRALBKDM4EXDHALDH1A1 | |
| SCHEMBL988148 | 0.75 | TTR (0.48) | TTRALBXDHMAPTHTT | |
| SCHEMBL1997670 | 0.75 | TTR (0.48) | TTRALBXDHEGLN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535637-B2 | Compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2022-12-27 | — | — | US | disclosed |
| US-20200216475-A1 | COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2020-07-09 | — | — | US | disclosed |
| EP-1861357-B1 | NOVEL COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORP (KR) | 2013-04-24 | — | — | EP | disclosed |
| US-7763657-B2 | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | AMOREPACIFIC CORPORATION (KR) | 2010-07-27 | — | — | US | disclosed |
| US-20090105258-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2009-04-23 | — | — | US | disclosed |
| WO-2007142426-A1 | NOVEL COMPOUNDS, ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2007-12-13 | — | — | WO | disclosed |
| EP-1862454-A1 | Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same | Amorepacific Corporation (KR) | 2007-12-05 | — | — | EP | disclosed |
| EP-1861357-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006101318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105258-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, VIPR1 | TTR 1818/4885ALB 4255/4885KDM4E 4685/4885 |
| US-11535637-B2 | Compound and organic light emitting element comprising same | NR2E3, NR4A2, NR2C2 | TTR 4279/4885ALB 4320/4885KDM4E 2586/4885 |
| US-20200216475-A1 | COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | NR2E3, NR4A2, NR4A1 | TTR 2849/4885ALB 3634/4885KDM4E 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.